霉酚酸酯联合培戈洛酶降低难治性痛风免疫原性的II期随机双盲安慰剂对照试验
本研究为II期随机双盲安慰剂对照试验,纳入32例接受培戈洛酶的难治性痛风患者,比较霉酚酸酯(MMF)与安慰剂的疗效。结果显示,12周时MMF组86%患者血清尿酸≤6 mg/dl,安慰剂组仅40%(P=0.01);24周时分别为68%和30%(P=0.06),不良事件率相似。
要点
- MMF联合培戈洛酶可显著提高12周血清尿酸≤6 mg/dl达标率(86% vs 40%,P=0.01)。
- 24周尿酸达标率MMF组68% vs 安慰剂组30%(P=0.06),差异未达统计学显著。
- 两组不良事件率相似,安慰剂组输注反应更多(30% vs 0%)。
核心结论
- MMF联合培戈洛酶耐受良好,在12周和24周时对血清尿酸≤6 mg/dl目标显示出有临床意义的改善。
研究设计与样本
- II期随机双盲安慰剂对照试验,32例接受至少一剂培戈洛酶的难治性痛风患者,按3:1随机接受MMF 1000 mg每日两次或安慰剂14周。
主要发现
- 12周时MMF组19/22例(86%)血清尿酸≤6 mg/dl,安慰剂组4/10例(40%)(P=0.01)。
- 24周时MMF组68%患者血清尿酸≤6 mg/dl,安慰剂组30%(P=0.06)。
- 两组不良事件率相似,安慰剂组输注反应发生率为30%,MMF组为0%。
关键数值与推荐
- 主要终点为12周时维持血清尿酸≤6 mg/dl的患者比例和不良事件率。
- MMF用法为1000 mg每日两次,从培戈洛酶前2周开始,持续14周;培戈洛酶8 mg每两周静脉给药12周。
临床怎么用
- 对于难治性痛风患者,在培戈洛酶治疗初期联合MMF可能提高12周尿酸达标率并减少输注反应。
局限性
- 样本量小(共32例),24周尿酸达标率差异未达统计学显著(P=0.06)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pegloticase is used for the treatment of severe gout, but its use is limited by immunogenicity. This study was undertaken to evaluate whether mycophenolate mofetil (MMF) prolongs the efficacy of pegloticase. METHODS: Participants were randomized 3:1 to receive 1,000 mg MMF twice daily or placebo for 14 weeks, starting 2 weeks before receiving pegloticase and continuing while receiving intravenous pegloticase 8 mg biweekly for 12 weeks. Participants then received pegloticase alone from week 12 to week 24. The primary end points were the proportion of patients who sustained a serum urate level of ≤6 mg/dl at 12 weeks and the rate of adverse events (AEs). Secondary end points included 24-week durability of serum urate level ≤6 mg/dl. Fisher's exact test and Wilcoxon's 2-sample test were used for analyses, along with Kaplan-Meier estimates and log rank tests. RESULTS: A total of 32 participants received ≥1 dose of pegloticase. Participants were predominantly men (88%), with a mean age of 55.2 years, mean gout duration of 13.4 years, and mean baseline serum urate level of 9.2 mg/dl. At 12 weeks, a serum urate level of ≤6 mg/dl was achieved in 19 (86%) of 22 participants in the MMF arm compared to 4 (40%) of 10 in the placebo arm (P = 0.01). At week 24, the serum urate level was ≤6 mg/dl in 68% of MMF-treated patients versus 30% of placebo-treated patients (P = 0.06), and rates of AEs were similar between groups, with more infusion reactions occurring in the placebo arm (30% versus 0%). CONCLUSION: Our findings indicate that MMF therapy with pegloticase is well tolerated and shows a clinically meaningful improvement in targeted serum urate level of ≤6 mg/dl at 12 and 24 weeks. This study suggests an innovative approach to pegloticase therapy in gout.
引用
- Khanna PP, Khanna D, Cutter G, et al. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021. PMID: 33750034. doi:10.1002/art.41731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。